Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Microalbuminuria and early renal response to lethal dose Shiga toxin type 2 in rats.

Ochoa F, Oltra G, Gerhardt E, Hermes R, Cohen L, Damiano AE, Ibarra C, Lago NR, Zotta E.

Int J Nephrol Renovasc Dis. 2012;5:29-36. doi: 10.2147/IJNRD.S27623. Epub 2012 Jan 19.

2.

Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.

Sauter KA, Melton-Celsa AR, Larkin K, Troxell ML, O'Brien AD, Magun BE.

Infect Immun. 2008 Oct;76(10):4469-78. doi: 10.1128/IAI.00592-08. Epub 2008 Aug 11.

3.

Characterization of stx2 tubular response in a rat experimental model of hemolytic uremic syndrome.

Ochoa F, Lago NR, Gerhardt E, Ibarra C, Zotta E.

Am J Nephrol. 2010;32(4):340-6. doi: 10.1159/000319444. Epub 2010 Aug 20.

PMID:
20733289
4.

Intraperitoneal administration of Shiga toxin 2 induced neuronal alterations and reduced the expression levels of aquaporin 1 and aquaporin 4 in rat brain.

Lucero MS, Mirarchi F, Goldstein J, Silberstein C.

Microb Pathog. 2012 Aug;53(2):87-94. doi: 10.1016/j.micpath.2012.05.005. Epub 2012 May 17.

PMID:
22610042
5.

Role of nitric oxide in shiga toxin-2-induced premature delivery of dead fetuses in rats.

Burdet J, Zotta E, Cella M, Franchi AM, Ibarra C.

PLoS One. 2010 Dec 29;5(12):e15127. doi: 10.1371/journal.pone.0015127.

6.

Cytokine expression in the renal tubular epithelial cells stimulated by Shiga toxin 2 of Escherichia coli O157:H7.

Lee JE, Kim JS, Choi IH, Tagawa M, Kohsaka T, Jin DK.

Ren Fail. 2002 Sep;24(5):567-75.

PMID:
12380901
7.

A clinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina.

Miceli S, Jure MA, de Saab OA, de Castillo MC, Rojas S, de Holgado AP, de Nader OM.

Jpn J Infect Dis. 1999 Apr;52(2):33-7.

PMID:
10816611
8.

Impaired endocytosis in proximal tubule from subchronic exposure to cadmium involves angiotensin II type 1 and cubilin receptors.

Santoyo-Sánchez MP, Pedraza-Chaverri J, Molina-Jijón E, Arreola-Mendoza L, Rodríguez-Muñoz R, Barbier OC.

BMC Nephrol. 2013 Oct 5;14:211. doi: 10.1186/1471-2369-14-211.

9.

Prevention of renal damage caused by Shiga toxin type 2: Action of Miglustat on human endothelial and epithelial cells.

Girard MC, Sacerdoti F, Rivera FP, Repetto HA, Ibarra C, Amaral MM.

Toxicon. 2015 Oct;105:27-33. doi: 10.1016/j.toxicon.2015.08.021. Epub 2015 Aug 31.

PMID:
26335361
10.

Systemic effects of Subtilase cytotoxin produced by Escherichia coli O113:H21.

Seyahian EA, Oltra G, Ochoa F, Melendi S, Hermes R, Paton JC, Paton AW, Lago N, Castro Parodi M, Damiano A, Ibarra C, Zotta E.

Toxicon. 2017 Mar 1;127:49-55. doi: 10.1016/j.toxicon.2016.12.014. Epub 2017 Jan 3.

PMID:
28057514
11.

Development of a Mouse Model of Shiga Toxin 2 (Stx2) Intoxication for Testing Therapeutic Agents Against Hemolytic Uremic Syndrome (HUS).

Mejias MP, Fernandez-Brando RJ, Ramos MV, Abrey-Recalde MJ, Zotta E, Meiss R, Palermo MS.

Curr Pharm Des. 2016;22(34):5294-5299.

PMID:
27356777
12.

Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.

Locatelli M, Buelli S, Pezzotta A, Corna D, Perico L, Tomasoni S, Rottoli D, Rizzo P, Conti D, Thurman JM, Remuzzi G, Zoja C, Morigi M.

J Am Soc Nephrol. 2014 Aug;25(8):1786-98. doi: 10.1681/ASN.2013050450. Epub 2014 Feb 27.

13.

Circulating plasma factors induce tubular and glomerular alterations in septic burns patients.

Mariano F, Cantaluppi V, Stella M, Romanazzi GM, Assenzio B, Cairo M, Biancone L, Triolo G, Ranieri VM, Camussi G.

Crit Care. 2008;12(2):R42. doi: 10.1186/cc6848. Epub 2008 Mar 25.

14.

Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice.

Melton-Celsa AR, Carvalho HM, Thuning-Roberson C, O'Brien AD.

Clin Vaccine Immunol. 2015 Apr;22(4):448-55. doi: 10.1128/CVI.00022-15. Epub 2015 Feb 25.

15.

Effects of Escherichia coli subtilase cytotoxin and Shiga toxin 2 on primary cultures of human renal tubular epithelial cells.

Márquez LB, Velázquez N, Repetto HA, Paton AW, Paton JC, Ibarra C, Silberstein C.

PLoS One. 2014 Jan 21;9(1):e87022. doi: 10.1371/journal.pone.0087022. eCollection 2014.

16.

Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.

Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI.

Pediatrics. 2005 Jun;115(6):e673-80.

PMID:
15930195
17.

The Effects of Shiga Toxin 1, 2 and Their Subunits on Cytokine and Chemokine Expression by Human Macrophage-Like THP-1 Cells.

Brandelli JR, Griener TP, Laing A, Mulvey G, Armstrong GD.

Toxins (Basel). 2015 Oct 9;7(10):4054-66. doi: 10.3390/toxins7104054.

18.

Progression of microalbuminuria in SHR is associated with lower expression of critical components of the apical endocytic machinery in the renal proximal tubule.

Inoue BH, Arruda-Junior DF, Campos LC, Barreto AL, Rodrigues MV, Krieger JE, Girardi AC.

Am J Physiol Renal Physiol. 2013 Jul 15;305(2):F216-26. doi: 10.1152/ajprenal.00255.2012. Epub 2013 May 1.

19.

Urinary concentrating defect in rats given Shiga toxin: elevation in urinary AQP2 level associated with polyuria.

Sugatani J, Komiyama N, Mochizuki T, Hoshino M, Miyamoto D, Igarashi T, Hoshi S, Miwa M.

Life Sci. 2002 May 31;71(2):171-89.

PMID:
12031687
20.

Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome.

Ludwig K, Sarkim V, Bitzan M, Karmali MA, Bobrowski C, Ruder H, Laufs R, Sobottka I, Petric M, Karch H, Müller-Wiefel DE.

J Clin Microbiol. 2002 May;40(5):1773-82.

Supplemental Content

Support Center